Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression
NCT07336238Phase 2Active, not recruiting
- Sponsor
- University of Washington
- Start
- May 2026
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in anxiety disorder and major depressive disorder (MDD), sponsored by University of Washington. Primary endpoint: Incidence of adverse events at 6 months. Started May 2026; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07336238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07336238.